Stock Analysis on Net

Allergan Inc. (NYSE:AGN.)

$22.49

This company has been moved to the archive! The financial data has not been updated since February 19, 2015.

Enterprise Value to FCFF (EV/FCFF)

Microsoft Excel

Paying users area

The data is hidden behind: . Unhide it.

  • Get 1-month access to Allergan Inc. for $22.49, or

  • get full access to the entire website for at least 3 months from $62.19.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Free Cash Flow to The Firm (FCFF)

Allergan Inc., FCFF calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Net earnings attributable to Allergan, Inc.
Net earnings attributable to noncontrolling interest
Net noncash charges
Changes in operating assets and liabilities
Net cash provided by operating activities
Cash paid for interest, net of amount capitalized, net of tax1
Interest capitalized, net of tax2
Additions to property, plant and equipment
Additions to capitalized software
Additions to intangible assets
Proceeds from sale of property, plant and equipment
Free cash flow to the firm (FCFF)

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

Item Description The company
FCFF Free cash flow to the firm is the cash flow available to the Allergan Inc. suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made. Allergan Inc. FCFF increased from 2012 to 2013 and from 2013 to 2014.

Interest Paid, Net of Tax

Allergan Inc., interest paid, net of tax calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Effective Income Tax Rate (EITR)
EITR1
Interest Paid, Net of Tax
Cash paid for interest, net of amount capitalized, before tax
Less: Cash paid for interest, net of amount capitalized, tax2
Cash paid for interest, net of amount capitalized, net of tax
Interest Costs Capitalized, Net of Tax
Interest capitalized, before tax
Less: Interest capitalized, tax3
Interest capitalized, net of tax

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

1 See details »

2 2014 Calculation
Cash paid for interest, net of amount capitalized, tax = Cash paid for interest, net of amount capitalized × EITR
= × =

3 2014 Calculation
Interest capitalized, tax = Interest capitalized × EITR
= × =


Enterprise Value to FCFF Ratio, Current

Allergan Inc., current EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in thousands)
Enterprise value (EV)
Free cash flow to the firm (FCFF)
Valuation Ratio
EV/FCFF
Benchmarks
EV/FCFF, Competitors1
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Zoetis Inc.

Based on: 10-K (reporting date: 2014-12-31).

1 Click competitor name to see calculations.

If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.


Enterprise Value to FCFF Ratio, Historical

Allergan Inc., historical EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Selected Financial Data (US$ in thousands)
Enterprise value (EV)1
Free cash flow to the firm (FCFF)2
Valuation Ratio
EV/FCFF3
Benchmarks
EV/FCFF, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Zoetis Inc.

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

1 See details »

2 See details »

3 2014 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =

4 Click competitor name to see calculations.

Valuation ratio Description The company
EV/FCFF Enterprise value to free cash flow to the firm is whole company valuation indicator. Allergan Inc. EV/FCFF ratio increased from 2012 to 2013 and from 2013 to 2014.